OmniAb, Inc.·Healthcare
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

OmniAb, Inc. (NASDAQ: OABI - Get Free Report) CEO Matthew Foehr sold 19,244 shares of the business's stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $1.49, for a total value of $28,673.56. Following the completion of the transaction, the chief executive officer owned 4,420,492 shares of the

OmniAb, Inc. (OABI) Q4 2025 Earnings Call Transcript

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.12 per share a year ago.

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the quarter and year ended December 31, 2025, and provided operating and partner program updates. “OmniAb exited 2025 with an expanded base of 107 active partners and a growing portfolio of 407 active programs. Our differentiated technologies support our business outlook and allow us to add programs while maintaining a disciplined cost structure. As our partner pipeline continues to advance, se.

OmniAb (NASDAQ: OABI - Get Free Report) is expected to be releasing its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $9.0030 million for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the quarter and year ended December 31, 2025, after the close of the U.S. financial markets on Wednesday, March 4, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss fourth quarter 2025 financial results and business updates Date: Wednesday, March 4, 2026 Time: 4:.